Abstract
Proteoglycans (PGs), glycosaminoglycans (GAGs) and hyaluronan as a free GAG, have unique structural characteristics which enable them via specific interactions with matrix proteins and cell surface receptors to regulate key tumor cell functions and thus to affect cancer growth and progression. This article explores the many layers of interdependent signaling among transformed colon epithelial cells, neighboring stromal cells and their respective PGs / GAGs components along the insidious and often deadly route of colon cancer progression. Specifically addressed is the altered deposition of PGs / GAGs by colon cancer cells; the effects of these malignant cells on gene expression and biosynthesis of PGs / GAGs of the surrounding stromal cells and the signaling pathways involved, with the utmost goal to highlight potential therapeutic targets in the rapidly developing field of glycan-based therapy.
Keywords: Colorectal cancer, glycosaminoglycans, proteoglycans, therapeutic targets, tumor cell signaling, hyaluronan, chondroitin sulfate, heparan sulfate, metastasis, glycan-based therapy
Current Medicinal Chemistry
Title:Insights into Targeting Colon Cancer Cell Fate at the Level of Proteoglycans / Glycosaminoglycans
Volume: 19 Issue: 25
Author(s): D. Nikitovic, G. Chatzinikolaou, J. Tsiaoussis, A. Tsatsakis, N. K. Karamanos and G. N. Tzanakakis
Affiliation:
Keywords: Colorectal cancer, glycosaminoglycans, proteoglycans, therapeutic targets, tumor cell signaling, hyaluronan, chondroitin sulfate, heparan sulfate, metastasis, glycan-based therapy
Abstract: Proteoglycans (PGs), glycosaminoglycans (GAGs) and hyaluronan as a free GAG, have unique structural characteristics which enable them via specific interactions with matrix proteins and cell surface receptors to regulate key tumor cell functions and thus to affect cancer growth and progression. This article explores the many layers of interdependent signaling among transformed colon epithelial cells, neighboring stromal cells and their respective PGs / GAGs components along the insidious and often deadly route of colon cancer progression. Specifically addressed is the altered deposition of PGs / GAGs by colon cancer cells; the effects of these malignant cells on gene expression and biosynthesis of PGs / GAGs of the surrounding stromal cells and the signaling pathways involved, with the utmost goal to highlight potential therapeutic targets in the rapidly developing field of glycan-based therapy.
Export Options
About this article
Cite this article as:
Nikitovic D., Chatzinikolaou G., Tsiaoussis J., Tsatsakis A., Karamanos N. K. and Tzanakakis G. N., Insights into Targeting Colon Cancer Cell Fate at the Level of Proteoglycans / Glycosaminoglycans, Current Medicinal Chemistry 2012; 19 (25) . https://dx.doi.org/10.2174/092986712802884268
DOI https://dx.doi.org/10.2174/092986712802884268 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Platinum-Based Agents for Individualized Cancer Treatment
Current Molecular Medicine Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Structural and Bioactive Properties of 3-O-Methylfunicone
Mini-Reviews in Medicinal Chemistry Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Peeking into the Black Box: How Cytokine Antibody Arrays Shed Light on Molecular Mechanisms of Breast Cancer Development and its Treatment
Current Proteomics Selectively Replicating Adenoviruses for Oncolytic Therapy
Current Cancer Drug Targets PPSu-PEG Copolymers and their Application in the Preparation of Cisplatin-loaded Nanoparticles
Current Nanoscience Tumor Treating Fields – Behind and Beyond Inhibiting the Cancer Cell Cycle
CNS & Neurological Disorders - Drug Targets miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Pharmacological Characterization of Histone Deacetylase Inhibitor and Tumor Cell-Growth Inhibition Properties of New Benzofuranone Compounds
Current Cancer Drug Targets First Molecular Cytogenetic Characterization of Murine Malignant Mesothelioma Cell Line AE17 and In Silico Translation to the Human Genome
Current Bioinformatics Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer
Current Cancer Drug Targets Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Computational & Statistical Methodologies to Identify Biomarkers in Cancer
Current Cancer Therapy Reviews Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
Current Cancer Drug Targets